(Q36362284)

13 August 2017

1 reference

title

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Amita Joshi

1

1 reference

13 August 2017

Robert Bauer

2

1 reference

13 August 2017

Peter Kuebler

3

1 reference

13 August 2017

Mark White

4

1 reference

13 August 2017

Cecelia Leddy

5

1 reference

13 August 2017

Peter Compton

6

1 reference

13 August 2017

Marvin Garovoy

7

1 reference

13 August 2017

Paul Kwon

8

1 reference

13 August 2017

Patricia Walicke

9

1 reference

13 August 2017

Russell Dedrick

10

1 reference

13 August 2017

publication date

1 January 2006

1 reference

The Journal of Clinical Pharmacology

13 August 2017

published in

1 reference

13 August 2017

volume

46

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

10-20

1 reference

The immunologic basis for the treatment of psoriasis with new biologic agents

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

The immunological synapse balances T cell receptor signaling and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Lymphocyte migration into tissue: the paradigm derived from CD4 subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283282

21 January 2018

Identifiers

DOI

10.1177/0091270005283282

1 reference

13 August 2017

1 reference